LMAT Stock Recent News

We avoid very high-yielding stocks, as the best way to grow richer over time is to own a diversified basket of dividend growth stocks. Today, we're highlighting a leading alternative asset manager, a niche medical devices company, and Michigan's largest regulated utility. Relative to our fair value estimates, the trio of fast-growing businesses are trading at 4% to 7% discounts.

LeMaitre's revenue and earnings continue to grow, though profit growth has moderated. The European launch of Artegraft and pending approval of XenoSure in China are key near-term catalysts. The portfolio's increasing share of biologic products combined with operational improvements are supporting high margins.

BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV.

LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago.

BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.

I've sold some higher-yielding stocks and reduced my portfolio yield in March. The goal was to get closer to my core strategy of investing only in companies with low dividend yields, but high dividend growth potential. While my portfolio yield decreased from 4% to 3.5%, my 5-year CAGR dividend growth rate went from 8% to 11%. Despite much uncertainty, the Canadian stock market has remained relatively strong since the beginning of the year.

LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.